
|Articles|September 1, 2003
Emerging Gold Standard?
San Francisco - More than two decades after collagen launched a revolution in filling facial wrinkles, the FDA is expected to approve the soft filler hyaluronic acid (Restylane, Q-Med) within the next few months. The approval will be partly based on a phase III study that showed it provides longer-lasting correction of nasolabial folds than collagen.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Demonstrates Positive Effects on TCS Use, Growth in Pediatric Patients
2
Arcutis Completes Enrollment in Phase 2 Study of Roflumilast Cream for Infant AD
3
Pilot Study Tests Oral NAC as Adjunct in Vitiligo Therapy
4
Brian Kim, MD, MTR, FAAD, on the Power of Focus in Research
5



















